Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lymph Node Assessment Clear all
Recruiting Not applicable Interventional

Refining Local-Regional Therapy for IBC

NCT04636710
View directory record Official record
Conditions
Breast Cancer, Inflammatory Breast Cancer, Sentinel Lymph Node
Interventions
Lymphoscintigraphy
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

NCT00847522
View directory record Official record
Conditions
Cancer
Interventions
Fluorescein
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 11, 2026, 9:04 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

NCT03991962
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 11, 2026, 9:04 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The SEQUENCE Trial

NCT06676956
View directory record Official record
Conditions
Pulmonary Nodules
Interventions
Linear EBUS first, Robotic-assisted bronchoscopy first
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Recruiting No phase listed Observational

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444
View directory record Official record
Conditions
Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Interventions
Guardant Reveal
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer

NCT02046057
View directory record Official record
Conditions
Breast Cancer
Interventions
PNB of SLN
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)

NCT04570722
View directory record Official record
Conditions
Breast Cancer, Melanoma, Thoracic Cancer, Lymphedema of Upper Arm
Interventions
Ipsilateral peripheral IV insertion
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 11, 2026, 9:04 AM EDT
Completed No phase listed Observational

Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling

NCT01156454
View directory record Official record
Conditions
Breast Cancer
Interventions
X-ray
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 11, 2026, 9:04 AM EDT
Completed No phase listed Observational

Tissue Biopsy and Imaging Studies in HIV-Infected Patients

NCT00001471
View directory record Official record
Conditions
HIV, ICL, Healthy Volunteers
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications

NCT03845907
View directory record Official record
Conditions
Breast Cancer
Interventions
Gen 1B, Gen 1
Device
Lead sponsor
Seno Medical Instruments Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2020 · Synced Sep 11, 2026, 9:04 AM EDT
Suspended No phase listed Observational

Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer

NCT05842031
View directory record Official record
Conditions
Penile Cancer
Interventions
Quality of Life Questionnaires, Patient Educational Needs, Symptom Management
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Completed No phase listed Observational

Role of Axumin PET Scan in Germ Cell Tumor

NCT03426865
View directory record Official record
Conditions
Testis Cancer, Germ Cell Tumor, Testicular Cancer, Germ Cell Tumor of Testis, Germ Cell Tumor, Testicular, Childhood, Testicular Neoplasms, Testicular Germ Cell Tumor, Testicular Yolk Sac Tumor, Testicular Choriocarcinoma, Testicular Diseases, Germ Cell Cancer Metastatic, Germ Cell Neoplasm of Retroperitoneum, Germ Cell Cancer, Nos
Interventions
Axumin PET scan
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 11, 2026, 9:04 AM EDT
Terminated Phase 1 Interventional

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

NCT03121677
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Personalized tumor vaccine, Poly ICLC, Nivolumab, Peripheral blood draws, Leukapheresis, Rituximab, Biopsy
Biological · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 11, 2026, 9:04 AM EDT
Active, not recruiting Phase 2 Interventional

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

NCT01871766
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Radiation, Bevacizumab, Sorafenib, Myeloid Growth Factor, Lymph Node Sampling, Irinotecan, Ifosfamide, Etoposide, Etoposide Phosphate, Doxorubicin, Dexrazoxane, ^1^1C-methionine
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
4
States / cities
Jacksonville, Florida • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Not listed Phase 1Phase 2 Interventional

VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer

NCT02294565
View directory record Official record
Conditions
Breast Cancer
Interventions
VST-1001, 99mTc-labeled sulfur colloid
Drug
Lead sponsor
Vestan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Phase 1 Interventional

Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

NCT02036918
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sipuleucel-T, Lymph Node Biopsy
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 11, 2026, 9:04 AM EDT
Terminated Not applicable Interventional Results available

Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound

NCT02218242
View directory record Official record
Conditions
Lung Cancer
Interventions
Intraoperative ultrasound
Device
Lead sponsor
Joel Thompson, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Phase 1 Interventional

Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.

NCT00000818
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2008 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

NCT00912418
View directory record Official record
Conditions
Melanoma
Interventions
autologous tumor cells plus GM-CSF-in Adjuvant
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 11, 2026, 9:04 AM EDT
Active, not recruiting Phase 3 Interventional

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874
View directory record Official record
Conditions
Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Procedure · Other · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
895
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer

NCT05800574
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Radiation therapy (5 days for 7 weeks), Radiation therapy (5 days for 6 weeks), Cisplatin
Radiation · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Completed Early Phase 1 Interventional

Fludeoxyglucose F 18 PET/CT Imaging in Finding Cancer in Patients Undergoing Surgery for Solid Tumors

NCT00816335
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
PET/CT scan, 18F-FDG Injection, Preoperative 18F-FDG PET/CT Scan, 18F-FDG for patients with Bladder Cancer, Surgical Procedure, Specimen PET/CT Scan
Procedure · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 11, 2026, 9:04 AM EDT
Recruiting Phase 1 Interventional

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

NCT07139990
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions
Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 11, 2026, 9:04 AM EDT
Completed No phase listed Observational

Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI

NCT02180308
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
PET/MRI
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 11, 2026, 9:04 AM EDT